Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Ruxolitinib
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Ruxolitinib 5mg tablets
0801050BIAAAAAA
|
Ruxolitinib | Ruxolitinib | Malignant Disease and Immunosuppression | 6 |
|
Ruxolitinib 15mg tablets
0801050BIAAABAB
|
Ruxolitinib | Ruxolitinib | Malignant Disease and Immunosuppression | 2 |
|
Jakavi 20mg tablets
0801050BIBBACAC
|
Jakavi | Ruxolitinib | Malignant Disease and Immunosuppression | 1 |
|
Jakavi 10mg tablets
0801050BIBBADAD
|
Jakavi | Ruxolitinib | Malignant Disease and Immunosuppression | No data available |
|
Jakavi 15mg tablets
0801050BIBBABAB
|
Jakavi | Ruxolitinib | Malignant Disease and Immunosuppression | No data available |
|
Jakavi 5mg tablets
0801050BIBBAAAA
|
Jakavi | Ruxolitinib | Malignant Disease and Immunosuppression | No data available |
|
Ruxolitinib 10mg tablets
0801050BIAAADAD
|
Ruxolitinib | Ruxolitinib | Malignant Disease and Immunosuppression | No data available |
|
Ruxolitinib 20mg tablets
0801050BIAAACAC
|
Ruxolitinib | Ruxolitinib | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.